Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720
J. Clin. Invest. Yong-Mi Kim, et al. 111:659 doi:10.1172/JCI16950 [
Go to this article.]
Figure 4FTY inhibits GvHD mortality while permitting GvL effects to be observed. Survival curves of nonleukemic control groups (
a) and leukemic groups (
b) are shown. (
a) Nonleukemic groups received syngeneic B6D2F1 BMCs (5 × 10
6) with either H
2O (open inverted triangles;
n = 7) or FTY (3 mg/kg/d; open circles;
n = 4); or they received allogeneic haplotype-mismatched C3D2F1 BMCs (5 × 10
6) and spleen cells (3 × 10
6) with either H
2O (filled squares;
n = 10) or 3 mg/kg/d FTY from day 0 until day 29 post-BMT (filled triangles;
n = 10). (
b) Leukemic groups received 5,000 EL4 cells on day 0. Mice received 5 × 10
6 syngeneic B6D2F1 BMCs alone (×’s;
n = 6) or with FTY (3 mg/kg/d; open diamonds;
n = 6). Allogeneic groups received haplotype-mismatched C3D2F1 BMCs (5 × 10
6) and spleen cells (1 × 10
6) with either H
2O (filled inverted triangles;
n = 10) or FTY treatment (*;
n = 10).
